Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydralazine + amlodipine
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Hydralazine + amlodipine is a combination of two antihypertensive medications used to treat high blood pressure. Hydralazine is a direct vasodilator that works by relaxing blood vessels, while amlodipine is a calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac muscle, resulting in vasodilation. This combination may be used when other blood pressure medications have not provided adequate control.
02
Targets
PHD1 (Prolyl hydroxylase domain-containing protein 1)CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on hydralazine + amlodipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydralazine + amlodipine.